Related Experiment Video
Updated: Jul 28, 2026
07:48
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
Expressing treatment-associated changes
S Chrubasik1, C Conradt, A Black
1Institute of Forensic Medicine, University of Freiburg, 79104 Freiburg, Germany. sigrun.chrubasik@klinikum.uni-freiburg.de
Zeitschrift Fur Rheumatologie
|September 27, 2005
Summary
Standardizing how treatment effects are reported in osteoarthritis research is crucial. Different methods for calculating effect size yield poor correlations and alter perceived treatment outcomes, necessitating clear guidelines.
Area of Science:
- Rheumatology
- Clinical Trials
- Biostatistics
Background:
- Osteoarthritis Research Society International (OARSI) seeks consensus on outcome measures for clinical studies.
- Lack of standardized methods for expressing effect size in osteoarthritis research hinders comparability.
Purpose of the Study:
- To evaluate different methods of expressing effect size for changes in outcome measures.
- To assess the impact of various expression methods on perceived treatment effect magnitudes.
Main Methods:
- Utilized data from a published study to calculate effect sizes using four distinct methods.
- Methods included dividing change from baseline by individual baseline or by the standard deviation (SD) of baseline, using both mean and median values.
Main Results:
- Correlations between the different effect size expression methods were poor.
- The perceived relative magnitude of treatment effects varied significantly depending on the chosen expression method.
Conclusions:
- Current methods for expressing effect size in osteoarthritis research are inconsistent.
- OARSI and other consensus organizations should recommend a standardized method for effect size expression.
- Authors must justify their chosen method or provide comprehensive data to ensure accurate interpretation of results.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...